Elisabeth Pasquier
Research Subjects
Elisabeth Pasquier has a total of 121 co-authors. Here are the top co-authors by number of shared publications:
Dominique Mottier
INSERM, Centre d'Investigation Clinique - 1412, Brest University Hospital, Brest, France
7 shared publicationsCaroline Bohec
Division of Gynaecology, François Mitterrand Hospital, Pau, France
6 shared publicationsLuc Bressollette
5 shared publicationsLuc de Saint Martin
From Brest University Hospital, Brest, France
5 shared publicationsLuc De Saint Martin
Université de Brest, EA 3878 (GETBO) Brest 29609, France
4 shared publications- Luc de Saint Martin
Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes Rares Nord et Ouest, Centre Hospitalier Régional et Universitaire de Brest, Université de Bretagne Occidentale, Brest, France
4 shared publications
Latest Publications
- 24 February 2026
- Published by Wiley in American Journal of Hematology
- Vol. 101 (5) , 1108-1113
Long Term Outcomes in Patients With Non‐Infectious Mixed Cryoglobulinemic Vasculitis
- 24 February 2026
- Published by Wiley in American Journal of Hematology
- Vol. 101 (5) , 1108-1113
Long Term Outcomes in Patients With Non‐Infectious Mixed Cryoglobulinemic Vasculitis
- 1 April 2021
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 42 (4) , 789-798
Whole exome sequencing, a hypothesis-free approach to investigate recurrent early miscarriage
- 1 April 2021
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 42 (4) , 789-798
Whole exome sequencing, a hypothesis-free approach to investigate recurrent early miscarriage
- Open Access
- 21 October 2019
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 86 (1) , 39-49
Hydroxychloroquine may be beneficial in preeclampsia and recurrent miscarriage
Recurrent miscarriage (RM) and vasculoplacental disorders, such as preeclampsia (PE), affect women of childbearing age worldwide. Vascular endothelial dysfunction and immunological impairment are associated with both RM and PE. To date, there is no effective or optimal therapeutic approach for these conditions. Notably, aspirin use is only partially effective in the prevention of PE. Hydroxychloroquine (HCQ) has demonstrated beneficial effects on disease flares, pregnancy outcomes and cardiovascular impairment in systemic erythaematosus lupus (SLE) through its immunomodulatory, vasculoprotective and antithrombotic properties. Here, in the context of the underlying physiological dysregulation associated with PE and RM, the beneficial properties and potential therapeutic efficacy of HCQ are reviewed in anticipation of the results of current and future trials. Two related trials addressing RM in the absence of maternal autoimmune disease are ongoing. Other trials addressing pregnancy outcomes in the presence of maternal autoimmune disease are forthcoming. In this review, we hypothesise that the immunological and endothelial effects of HCQ may be beneficial in the context of PE and RM, regardless of the maternal autoimmune status.
- 21 October 2019
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 86 (1) , 39-49
Open AccessHydroxychloroquine may be beneficial in preeclampsia and recurrent miscarriage
Recurrent miscarriage (RM) and vasculoplacental disorders, such as preeclampsia (PE), affect women of childbearing age worldwide. Vascular endothelial dysfunction and immunological impairment are associated with both RM and PE. To date, there is no effective or optimal therapeutic approach for these conditions. Notably, aspirin use is only partially effective in the prevention of PE. Hydroxychloroquine (HCQ) has demonstrated beneficial effects on disease flares, pregnancy outcomes and cardiovascular impairment in systemic erythaematosus lupus (SLE) through its immunomodulatory, vasculoprotective and antithrombotic properties. Here, in the context of the underlying physiological dysregulation associated with PE and RM, the beneficial properties and potential therapeutic efficacy of HCQ are reviewed in anticipation of the results of current and future trials. Two related trials addressing RM in the absence of maternal autoimmune disease are ongoing. Other trials addressing pregnancy outcomes in the presence of maternal autoimmune disease are forthcoming. In this review, we hypothesise that the immunological and endothelial effects of HCQ may be beneficial in the context of PE and RM, regardless of the maternal autoimmune status.
- 1 August 2019
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 39 (2) , 304-311
Blood anti-Müllerian hormone is a possible determinant of recurrent early miscarriage, yet not conclusive in predicting a further miscarriage
- 1 August 2019
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 39 (2) , 304-311
Blood anti-Müllerian hormone is a possible determinant of recurrent early miscarriage, yet not conclusive in predicting a further miscarriage
- Open Access
Hydroxychloroquine for prevention of recurrent miscarriage: study protocol for a multicentre randomised placebo-controlled trial BBQ study
Introduction Recurrent miscarriage (RM), defined by three or more consecutive losses during the first trimester of pregnancy, affects 1%–2% of fertile couples. Standard investigations fail to reveal any apparent cause in ~50% of couples. However, on the basis of animal models and clinical studies, several hypotheses have been put forward concerning underlying mechanisms of RM: altered ovarian reserve, progesterone defect, thrombotic and/or endothelial dysfunction and immunological disturbances. Nonetheless, no study has yet reached conclusive beneficial clinical evidence for a potential treatment in unexplained RM. Hydroxychloroquine (HCQ) is a molecule with extensive safety data during pregnancy. The pharmacological properties of HCQ (eg, antithrombotic, vascular protective, immunomodulatory, improved glucose tolerance, lipidlowering and anti-infectious) could be effective against some mechanisms of unexplained RM. Furthermore, eventhough clinical benefit of HCQ is suggested in prevention of thrombotic and late obstetric events in antiphospholipid (APL) syndrome, there are no data suggesting the benefit of HCQ in RM in the presence of APL antibodies. Methods and analysis Taken all together and given the low cost of HCQ, the aim of this multicentre, randomised, placebo-controlled, double-blind study is to investigate whether HCQ would improve the live birth rate in women with RM, irrespective of maternal thrombophilic status: (1) no known thrombophilia, (2) inherited thrombophilia or (3) APL antibodies. The primary end point is a live and viable birth. After confirming eligibility and obtaining consent, 300 non-pregnant women will be randomised into two parallel groups for a daily oral treatment (HCQ 400 mg or placebo), initiated before conception and stopped at 10 weeks’ gestation. If pregnancy does not occur after 1 year, the treatment will be stopped. Ethics and dissemination Agreement from the French National Public Health and Drug Security Agency (160765A-22) and ethical approval from the Committee for the Protection of Persons of NORD-OUEST I (2016-001330-97) have been obtained. Trial registration numbers NCT0316513; Pre-results.
Open AccessHydroxychloroquine for prevention of recurrent miscarriage: study protocol for a multicentre randomised placebo-controlled trial BBQ study
Introduction Recurrent miscarriage (RM), defined by three or more consecutive losses during the first trimester of pregnancy, affects 1%–2% of fertile couples. Standard investigations fail to reveal any apparent cause in ~50% of couples. However, on the basis of animal models and clinical studies, several hypotheses have been put forward concerning underlying mechanisms of RM: altered ovarian reserve, progesterone defect, thrombotic and/or endothelial dysfunction and immunological disturbances. Nonetheless, no study has yet reached conclusive beneficial clinical evidence for a potential treatment in unexplained RM. Hydroxychloroquine (HCQ) is a molecule with extensive safety data during pregnancy. The pharmacological properties of HCQ (eg, antithrombotic, vascular protective, immunomodulatory, improved glucose tolerance, lipidlowering and anti-infectious) could be effective against some mechanisms of unexplained RM. Furthermore, eventhough clinical benefit of HCQ is suggested in prevention of thrombotic and late obstetric events in antiphospholipid (APL) syndrome, there are no data suggesting the benefit of HCQ in RM in the presence of APL antibodies. Methods and analysis Taken all together and given the low cost of HCQ, the aim of this multicentre, randomised, placebo-controlled, double-blind study is to investigate whether HCQ would improve the live birth rate in women with RM, irrespective of maternal thrombophilic status: (1) no known thrombophilia, (2) inherited thrombophilia or (3) APL antibodies. The primary end point is a live and viable birth. After confirming eligibility and obtaining consent, 300 non-pregnant women will be randomised into two parallel groups for a daily oral treatment (HCQ 400 mg or placebo), initiated before conception and stopped at 10 weeks’ gestation. If pregnancy does not occur after 1 year, the treatment will be stopped. Ethics and dissemination Agreement from the French National Public Health and Drug Security Agency (160765A-22) and ethical approval from the Committee for the Protection of Persons of NORD-OUEST I (2016-001330-97) have been obtained. Trial registration numbers NCT0316513; Pre-results.
- 1 December 2018
- Published by Elsevier in La Revue de Médecine Interne
- Vol. 39 (12) , 935-941
Prévention de la pré-éclampsie en 2018 en population générale et chez la femme lupique : à l’aube d’une médecine personnalisée ?
- 1 December 2018
- Published by Elsevier in La Revue de Médecine Interne
- Vol. 39 (12) , 935-941
Prévention de la pré-éclampsie en 2018 en population générale et chez la femme lupique : à l’aube d’une médecine personnalisée ?
- 23 September 2017
- Published by Elsevier in Thrombosis Research
- Vol. 159, 122-123
Much ado about antithrombotic therapy in pregnancy
- 23 September 2017
- Published by Elsevier in Thrombosis Research
- Vol. 159, 122-123
Much ado about antithrombotic therapy in pregnancy
- 15 September 2015
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 163 (6) , 484-485
Low-Molecular-Weight Heparin for Women With Unexplained Recurrent Pregnancy Loss
- 15 September 2015
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 163 (6) , 484-485
Low-Molecular-Weight Heparin for Women With Unexplained Recurrent Pregnancy Loss
- Open Access
- 2 April 2015
- Published by American Society of Hematology in Blood
- Vol. 125 (14) , 2200-2205
Enoxaparin for prevention of unexplained recurrent miscarriage: a multicenter randomized double-blind placebo-controlled trial
Key Points: The use of low-molecular-weight heparin did not improve live-birth rates in nonthrombophilic women with consecutive recurrent miscarriage. Prophylactic doses of low-molecular-weight heparin should no longer be prescribed in this clinical setting.
- 2 April 2015
- Published by American Society of Hematology in Blood
- Vol. 125 (14) , 2200-2205
Open AccessEnoxaparin for prevention of unexplained recurrent miscarriage: a multicenter randomized double-blind placebo-controlled trial
Key Points: The use of low-molecular-weight heparin did not improve live-birth rates in nonthrombophilic women with consecutive recurrent miscarriage. Prophylactic doses of low-molecular-weight heparin should no longer be prescribed in this clinical setting.